Overview

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

Status:
Active, not recruiting

Trial end date:
2023-11-01

Target enrollment:

Participant gender:

Summary

This pilot phase II trial studies ibrutinib in treating patients with transformed indolent (a type of cancer that grows slowly) B-cell non-Hodgkin lymphoma that have returned after a period of improvement (relapsed) or do not respond to treatment (refractory). Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes (proteins) needed for cell growth.

Phase:

Phase 2

Details

Lead Sponsor:

University of Washington

Collaborators:

Janssen Pharmaceuticals
National Cancer Institute (NCI)